Current State and Future Opportunities in Granulocyte Colony-stimulating Factor (G-CSF)

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2022 Jun 23

PMID 35739328

Authors

Hartmut Link

Affiliations

Soon will be listed here.

Citing Articles

Granulocyte colony-stimulating factor combined with SOFA score for mortality prediction in patients with sepsis.

Fu X, Zhang Y, Wang J, Liu Y, Wei B Medicine (Baltimore). 2025; 103(52):e40926.

PMID: 39969364 PMC: 11688010. DOI: 10.1097/MD.0000000000040926.

Outcomes of Patients with Hematological Malignancies Admitted to the Intensive Care Unit at a Tertiary Care Center in Saudi Arabia.

Alotaibi G, Alekrish Y, Aldokhayel F, Alassaf A, Alzahrani M, Aljabry M Saudi J Med Med Sci. 2025; 13(1):47-52.

PMID: 39935991 PMC: 11809755. DOI: 10.4103/sjmms.sjmms_257_24.

Filgrastim Efficiency in Cats Naturally Infected with Feline Panleukopenia Virus.

Dascalu M, Daraban Bocaneti F, Soreanu O, Tutu P, Cozma A, Morosan S Animals (Basel). 2025; 14(24.

PMID: 39765486 PMC: 11672453. DOI: 10.3390/ani14243582.

Literature review analysis of aortitis induced by granulocyte-colony stimulating factor.

Zhao T, Xu H Front Pharmacol. 2025; 15:1487501.

PMID: 39744136 PMC: 11688214. DOI: 10.3389/fphar.2024.1487501.

Effect of granulocyte colony-stimulating factor (G-CSF) in functional outcome of acute spinal cord injury patients: A single-blinded randomized controlled trial.

Mounissamy P, Premraj A, Chanadrashekar S, Jeyaraman N, Ramasubramanian S, Jeyaraman M J Orthop. 2024; 64:97-101.

PMID: 39691645 PMC: 11648636. DOI: 10.1016/j.jor.2024.11.025.

References

Ghidini M, Indini A, Nigro O, Polito S, Rijavec E, Petrelli F . Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. Expert Opin Pharmacother. 2021; 22(7):857-865. DOI: 10.1080/14656566.2021.1873950. View

. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019; 393(10179):1440-1452. PMC: 6451189. DOI: 10.1016/S0140-6736(18)33137-4. View

Link H, Illerhaus G, Martens U, Salar A, Depenbusch R, Kohler A . Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Support Care Cancer. 2020; 29(5):2519-2527. PMC: 7981320. DOI: 10.1007/s00520-020-05711-7. View

Yarza R, Bover M, Paredes D, Lopez-Lopez F, Jara-Casas D, Castelo-Loureiro A . SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer. 2020; 135:242-250. PMC: 7275164. DOI: 10.1016/j.ejca.2020.06.001. View

Bajrami B, Zhu H, Kwak H, Mondal S, Hou Q, Geng G . G-CSF maintains controlled neutrophil mobilization during acute inflammation by negatively regulating CXCR2 signaling. J Exp Med. 2016; 213(10):1999-2018. PMC: 5030805. DOI: 10.1084/jem.20160393. View

Zhang A, Morjaria S, Kaltsas A, Hohl T, Parameswaran R, Patel D . The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With Coronavirus Disease 2019 (COVID-19) Infection. Clin Infect Dis. 2021; 74(4):567-574. PMC: 8406899. DOI: 10.1093/cid/ciab534. View

Gurion R, Belnik-Plitman Y, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I . Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. 2012; (6):CD008238. PMC: 7390444. DOI: 10.1002/14651858.CD008238.pub3. View

Pahnke S, Egeland T, Halter J, Hagglund H, Shaw B, Woolfrey A . Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. Bone Marrow Transplant. 2018; 54(6):858-866. DOI: 10.1038/s41409-018-0350-y. View

Lieschke G, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C . Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood. 1994; 84(6):1737-46. View

10.

Lapidari P, Vaz-Luis I, Di Meglio A . Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. Crit Rev Oncol Hematol. 2020; 157:103193. DOI: 10.1016/j.critrevonc.2020.103193. View

11.

Link H, Kerkmann M, Holtmann L, Ortner P . G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer. 2018; 27(4):1459-1469. PMC: 6394812. DOI: 10.1007/s00520-018-4481-x. View

12.

Fried S, Avigdor A, Bielorai B, Meir A, Besser M, Schachter J . Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54(10):1643-1650. DOI: 10.1038/s41409-019-0487-3. View

13.

Smith T, Khatcheressian J, Lyman G, Ozer H, Armitage J, Balducci L . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19):3187-205. DOI: 10.1200/JCO.2006.06.4451. View

14.

Wierda W, Tambaro F . How I manage CLL with venetoclax-based treatments. Blood. 2020; 135(17):1421-1427. PMC: 11311481. DOI: 10.1182/blood.2019002841. View

15.

Molineux G . Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs. 2003; 14(4):259-64. DOI: 10.1097/00001813-200304000-00002. View

16.

GABRILOVE J, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J . Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988; 318(22):1414-22. DOI: 10.1056/NEJM198806023182202. View

17.

Trivedi M, Martinez S, Corringham S, Medley K, Ball E . Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant. 2009; 43(12):895-908. DOI: 10.1038/bmt.2009.75. View

18.

Levesque J, Hendy J, Takamatsu Y, Simmons P, Bendall L . Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003; 111(2):187-96. PMC: 151860. DOI: 10.1172/JCI15994. View

19.

Frasci G, Comella P, DAiuto G, Budillon A, Barbarulo D, Thomas R . Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Cancer Res Treat. 1998; 49(1):13-26. DOI: 10.1023/a:1005945218155. View

20.

Griffiths E, Alwan L, Bachiashvili K, Brown A, Cool R, Curtin P . Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. J Natl Compr Canc Netw. 2020; :1-4. PMC: 9730290. DOI: 10.6004/jnccn.2020.7610. View